A double-blind short-term presurgical study to assess the molecular predictors of the antiproliferative effects of lapatinib in women with primary breast cancer

Trial Profile

A double-blind short-term presurgical study to assess the molecular predictors of the antiproliferative effects of lapatinib in women with primary breast cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 06 May 2016

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Early breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms MAPLE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Apr 2012 Results presented at the 103rd Annual Meeting of the American Association for Cancer Research.
    • 18 Aug 2011 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top